furazolidone has been researched along with Heart Failure in 8 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 5.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 5.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "We have previously demonstrated that in furazolidone-induced congestive heart failure in turkeys the specific Ca(2+)-ATPase activity of myocardial sarcoplasmic reticulum (SR) is 60% increased in compensation for a 50% depression in net Ca(2+)-sequestration activity." | 3.68 | Myocardial calcium cycling defect in furazolidone cardiomyopathy. ( Julian, RJ; Mirsalimi, SM; O'Brien, PJ; Shen, H; Weiler, JE, 1991) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 1.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 1.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "Newly hatched male White Pekin ducklings were fed furazolidone (FZ) at dosage of 750 mg/kg of feed for 4 weeks." | 1.27 | Furazolidone-induced congestive cardiomyopathy in ducklings: myocardial ultrastructural alterations. ( Ferrans, VJ; Van Vleet, JF, 1983) |
| "Free carnitine was elevated by 126% in left ventricle and by 54% in skeletal muscle of the furazolidone-treated turkeys (p less than 0." | 1.27 | Carnitine alterations in spontaneous and drug-induced turkey congestive cardiomyopathy. ( Borgwardt, B; Einzig, S; Judd, D; Noren, GR; Pierpont, ME; Staley, NA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okafor, CC | 1 |
| Perreault-Micale, C | 1 |
| Hajjar, RJ | 2 |
| Lebeche, D | 1 |
| Skiroman, K | 1 |
| Jabbour, G | 1 |
| Doye, AA | 1 |
| Lee, MX | 1 |
| Laste, N | 1 |
| Gwathmey, JK | 2 |
| Van Vleet, JF | 3 |
| Ferrans, VJ | 3 |
| O'Brien, PJ | 2 |
| O'Grady, M | 1 |
| Lumsden, JH | 1 |
| Holmberg, DL | 1 |
| Shen, H | 2 |
| Weiler, JE | 2 |
| Horn, RD | 1 |
| Mirsalimi, SM | 2 |
| Julian, RJ | 2 |
| Kim, CS | 1 |
| Khan, F | 1 |
| DiSalvo, TG | 1 |
| Matsumori, A | 1 |
| Bristow, MR | 1 |
| Pierpont, ME | 1 |
| Judd, D | 1 |
| Borgwardt, B | 1 |
| Noren, GR | 1 |
| Staley, NA | 1 |
| Einzig, S | 1 |
8 other studies available for furazolidone and Heart Failure
| Article | Year |
|---|---|
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2003 |
Furazolidone-induced congestive cardiomyopathy in ducklings: regression of cardiac lesions after cessation of furazolidone ingestion.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Ducks; Furazolidone; Heart Failure; Male; Myocard | 1983 |
Furazolidone-induced congestive cardiomyopathy in ducklings: myocardial ultrastructural alterations.
Topics: Animals; Cardiomyopathies; Ducks; Furazolidone; Heart Failure; Male; Myocardium; Myofibrils; Poultry | 1983 |
Furazolidone-induced congestive cardiomyopathy in ducklings: lack of protection from selenium, vitamin E, and taurine supplements.
Topics: Animals; Cardiomyopathies; Ducks; Furazolidone; Heart Failure; Male; Poultry Diseases; Selenium; Tau | 1983 |
Clinical pathologic profiles of dogs and turkeys with congestive heart failure, either noninduced or induced by rapid ventricular pacing, and turkeys with furazolidone toxicosis.
Topics: Animals; Cardiac Pacing, Artificial; Dog Diseases; Dogs; Female; Furazolidone; Heart Failure; Male; | 1993 |
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Blood Pressure; Bod | 1999 |
Myocardial calcium cycling defect in furazolidone cardiomyopathy.
Topics: Animals; Calcium; Calcium Channels; Calcium-Transporting ATPases; Cardiomyopathies; Disease Models, | 1991 |
Carnitine alterations in spontaneous and drug-induced turkey congestive cardiomyopathy.
Topics: Animals; Cardiomyopathy, Dilated; Carnitine; Furazolidone; Heart Failure; Hemodynamics; Liver; Myoca | 1985 |